Study guide
Contraceptive choice and missed pills
AMC CAT MCQ Examination AMC Part 1
Track your progress as you read
Finished sections get a check mark.
1 Acute Coronary Syndromes & ECG Localization
ACS recognition and ECG localisation Reperfusion and infarction complications
2 Heart Failure, Cardiogenic Shock & Cardiac Arrhythmias
Heart failure assessment and treatment Arrhythmias and conduction emergencies
3 Systemic Hypertension & Peripheral Vascular Disease
Blood pressure and cardiovascular risk Secondary hypertension and arterial disease
4 Valvular Heart Disease, Infective Endocarditis & Pericarditis
Aortic and mitral valve disease Endocarditis and pericardial emergencies
5 Asthma & COPD Acute Flares and Maintenance
Asthma and COPD diagnosis and maintenance Acute asthma and COPD exacerbations
6 Pneumonia, pleural disease and respiratory failure
Pneumonia and infected pleural collections Pulmonary embolism, effusions and pneumothorax Respiratory failure, ARDS and sepsis
7 GI bleeding, bowel inflammation and malabsorption
GI bleeding assessment and resuscitation Varices, ulcers, reflux and lower GI bleeding IBD patterns and severe colitis assessment IBD treatment, coeliac disease and IBS
8 Chronic Liver Disease, Cirrhosis Complications & Acute Hepatitis
Cirrhosis diagnosis and prognosis Decompensation, viral hepatitis and surveillance
9 Diabetes, thyroid and adrenal disease
Diabetes diagnosis and ongoing care DKA, HHS and complication monitoring Thyroid disease assessment Thyroid emergencies and adrenal disease
10 Acute Kidney Injury, Chronic Kidney Disease & Fluid/Electrolyte Emergencies
AKI and chronic kidney disease Potassium and sodium emergencies
11 Anaemias, Inflammatory Arthropathies & Geriatric Comprehensive Assessment
Anaemia, bruising and blood disorders Arthritis, autoimmune disease and geriatric care
12 Evaluation of the Acute Abdomen, Peritonitis & Appendicitis
Abdominal pain, peritonitis and resuscitation Appendicitis diagnosis and treatment Perforation and mesenteric ischaemia
13 Small and Large Bowel Obstruction & Colorectal Surgical Pathology
Small bowel obstruction Colonic obstruction, volvulus and cancer recognition Colorectal care, diverticulitis and anorectal symptoms
14 Gallbladder Disease, Biliary Tract Infections & Acute Pancreatitis
Gallstones and biliary obstruction Cholangitis and pancreatitis diagnosis Pancreatitis severity and treatment
15 Advanced Trauma Life Support, Primary Survey & Life-Threatening Thoracic Injuries
Trauma primary survey and adjuncts Chest trauma and immediate threats
16 Traumatic Brain Injury, Intracranial Haemorrhage & Spinal Cord Clearance
Head injury, imaging and haemorrhage Herniation and spinal cord injury
17 Major Fractures, Joint Dislocations & Acute Compartment Syndrome
Fracture assessment and open injuries Compartment syndrome, dislocations and pelvic injury
18 Thermal Burns, Haemorrhagic Shock Resuscitation & Surgical Wound Care
Burn assessment and fluid resuscitation Bleeding shock, wound care and tetanus
19 Aortic Aneurysms & Acute Arterial Limb Ischaemia
Aneurysm recognition and planned care Ruptured aneurysm and acute limb ischaemia
20 Urological Emergencies, Testicular Torsion & Haematuria Investigation
Retention, stones and obstructed infection Scrotal pain and haematuria
21 Preoperative Risk Stratification & Postoperative Surgical Complications
Preoperative assessment and medicines Postoperative complications and prevention
22 Early Pregnancy Bleeding, Ectopic Pregnancy & Antenatal Screening
Miscarriage and ectopic pregnancy Antenatal screening and early-pregnancy comparisons
23 Hypertensive Disorders of Pregnancy & Medical Complications in Pregnancy
Pregnancy hypertension and preeclampsia Eclampsia, HELLP and antepartum bleeding
24 Intrapartum Monitoring, Postpartum Haemorrhage & Obstetric Emergencies
Labour physiology and CTG assessment CTG response and postpartum haemorrhage Obstetric emergencies and preterm birth
25 Abnormal Uterine Bleeding, Pelvic Pain & Endometriosis
Abnormal bleeding and structural causes Endometrial sampling and endometriosis PCOS diagnosis and long-term care
26 Contraception, Emergency Contraception & Pregnancy Termination
Contraceptive choice and missed pills Emergency contraception and abortion
27 Australian Cervical Screening Program & Gynaecological Malignancies
Cervical screening and cervical cancer Endometrial and ovarian cancer
28 Neonatal Resuscitation, Congenital Conditions & Neonatal Jaundice
Newborn resuscitation, Apgar and cyanosis Neonatal jaundice assessment Jaundice treatment and congenital screening
29 Developmental Milestones, Growth Charts & Failure to Thrive
Developmental milestones Regression, autism and support Faltering growth and developmental comparisons
30 The Limping Child, Septic Arthritis vs Transient Synovitis & Paediatric Hip Conditions
Limp assessment and septic-joint risk Joint-infection management and Perthes disease SUFE and paediatric hip comparisons
31 Croup, Bronchiolitis, Paediatric Asthma & Anaphylaxis
Croup Bronchiolitis Paediatric asthma Paediatric anaphylaxis
32 Evaluation of the Febrile Child, Sepsis & Meningococcal Disease
Febrile neonates and young infants Meningococcal disease and paediatric sepsis Bacterial meningitis and CSF interpretation Kawasaki disease and follow-up
33 Paediatric Surgical Abdomen, Dehydration & Child Protection / Non-Accidental Injury
Pyloric stenosis Intussusception and dehydration Child protection and injury assessment
34 The Mental State Examination & Suicide Risk Stratification
Mental state examination and psychotic symptoms Suicide formulation and mental health law
35 Major Depressive Disorder, Bipolar Affective Disorder & Mood Stabilisers
Depression assessment and treatment Serotonin toxicity and bipolar presentations Mood stabilisers and ECT
36 Generalised Anxiety, Panic Disorder, PTSD & Obsessive-Compulsive Disorder
Anxiety, panic and agoraphobia OCD and trauma-related disorders
37 Schizophrenia, Acute Psychosis & Antipsychotic Management
Psychosis assessment and antipsychotics Clozapine and severe adverse effects
38 Substance Use Disorders & Acute Withdrawal Syndromes
Substance disorders and alcohol withdrawal Wernicke disease, opioids and stimulants
39 Delirium vs Dementia, Perinatal Mood Disorders & Paediatric Psychiatry
Delirium and dementia assessment Cognitive behaviour, perinatal and childhood psychiatry
40 Medicare, PBS, AHPRA & Good Medical Practice Framework
Australian health services and Medicare PBS access and professional registration Professional boundaries and notifications
41 Informed Consent (Rogers v Whitaker), Mental Capacity & Involuntary Treatment
Consent, material risks and young people Capacity, refusal and substitute decisions
42 Patient Privacy, Confidentiality Exceptions & Mandatory Notifications
Privacy, disclosure and child reporting Driving fitness and threat disclosure
43 First Nations health and preventive care
First Nations health, determinants and cultural safety Community care, Item 715 and CTG medicines Immunisation and cancer screening entry points Screening pathways and primary CVD prevention
44 Epidemiological Metrics, Clinical Study Designs & Notifiable Communicable Diseases
Epidemiology, calculations, bias and surveillance
45 Neurological presentations
Stroke, TIA and focal weakness Headache, facial pain and vertigo Seizures, collapse and altered consciousness Numbness, movement disorders and generalised weakness
46 Musculoskeletal pain
Back, neck, bone and soft tissue pain
47 Eye presentations
Altered vision and retinal disease Red eye, ocular injury and discharge
48 Ear, nose, throat and oral health
Ear pain, hearing loss and tinnitus Nasal problems, neck lumps, hoarseness and dysphagia Toothache, mouth symptoms, dry mouth and halitosis
49 Skin, hair and nails
Rash, itch, infection and skin ulcers Skin lesions, hair loss and nail abnormalities
50 Breast health and feeding
Breast lumps, discharge and breastfeeding problems
51 Sexual and reproductive presentations
Genital symptoms, discharge and pelvic infection Menopause, prolapse and urinary symptoms Infertility and sexual dysfunction
52 Palliative care and carers
The dying patient, symptoms and carers
53 Eating disorders and personality care
Eating disorders, obesity and weight change Personality difficulties, self-harm and complex care
54 Sleep presentations
Insomnia, snoring and daytime sleepiness
55 Poisoning, resuscitation and environmental emergencies
Poisoning, toxidromes and antidote decisions Cardiopulmonary arrest, choking and emergency help Bites, stings, heat, cold and drowning
56 Communication, rights and professional practice
Communication, handover, errors and complaints Healthcare rights, inclusive care and equitable access Certificates, deaths, CPD and supervision Telehealth, images, prescribing and doctors' health
57 Genetics, research and donation
Genetic testing, research and organ donation
58 Travel, fever and outbreaks
Fever, travellers and outbreak response
Contraceptive choice and missed pills
Key Takeaways Explain This Topic AI
Migraine with aura is a contraindication to combined hormonal contraception.
The Australian etonogestrel implant is licensed for three years.
Mirena's contraceptive duration differs from its heavy-bleeding and endometrial-protection indications.
Last updated: October 2026
Contraception, Emergency Contraception & Pregnancy Termination
Contraceptive eligibility: Use the current Australian clinical resource and the MEC framework it adopts, noting that WHO and UK classifications differ in detail. Core CHC contraindications include migraine with aura, severe hypertension and current breast cancer. Past disease, VTE on treatment and complicated diabetes need their specific category and circumstances rather than one universal label.
Long-Acting Reversible Contraception (LARC)
Long-acting reversible contraceptives (LARCs) are the most effective methods of reversible fertility control because their clinical efficacy does not depend on daily compliance, coital timing, or frequent administration. Australian national guidelines strongly advocate for LARCs as first-line options for all individuals seeking contraception, including nulliparous women and adolescents.
Etonogestrel Subdermal Implant (Implanon NXT)
Pharmacology & Duration : A single radiopaque rod ( 4 cm × 2 mm 4\text{ cm} \times 2\text{ mm} 4 cm × 2 mm ) containing 68 mg 68\text{ mg} 68 mg of etonogestrel (the active metabolite of desogestrel). Licensed in Australia for 3 years of continuous use.
Efficacy : The most effective reversible contraceptive available, with a failure rate of < 0.05 % < 0.05\% < 0.05% (higher efficacy than surgical sterilization).
Mechanism of Action :
Complete suppression of ovulation via inhibition of the mid-cycle luteinizing hormone (LH) surge.
Rapid thickening of cervical mucus, preventing sperm ascent into the upper reproductive tract.
Induction of an atrophic, hostile endometrial lining.
Bleeding Patterns & Clinical Management : Unscheduled bleeding is the most common reason for premature discontinuation (~20% of users experience amenorrhoea, ~50% experience infrequent or light bleeding, and ~20% to 30% experience frequent or prolonged bleeding). Management of bothersome prolonged bleeding includes ruling out pregnancy and sexually transmitted infections (STIs), followed by a 3-month course of low-dose combined oral contraceptive pills (COCP) or a short course of oral mefenamic acid ( 500 mg 500\text{ mg} 500 mg TDS) or tranexamic acid ( 1 g 1\text{ g} 1 g TDS) taken during bleeding episodes.
Fertility Return : Rapid return of fertility, with ovulatory cycles resuming within weeks of removal.
Levonorgestrel Intrauterine System (LNG-IUS)
Available Devices in Australia :
Mirena: Licensed for eight years of contraception and five years for heavy menstrual bleeding. Duration for endometrial protection during menopausal hormone therapy is a separate indication; confirm current Australian product information and specialist guidance.
Kyleena ( 19.5 mg 19.5\text{ mg} 19.5 mg LNG) : Smaller frame and narrower insertion tube (suitable for nulliparous individuals with a small cervical canal). Licensed for 5 years for contraception.
Mechanism of Action : Primarily a profound local progestogenic effect resulting in glandular endometrial atrophy and dense stromal decidualization, rendering the endometrium unreceptive to implantation. It also thickens cervical mucus. Most women continue to ovulate spontaneously because systemic progestogen absorption is minimal.
Clinical Indications : Extremely effective contraception (failure rate < 0.2 % < 0.2\% < 0.2% ). Mirena is the recognized medical first-line therapy for heavy menstrual bleeding, reducing objective menstrual blood loss by > 90 % > 90\% > 90% within 6 months, and is highly effective in managing pain associated with adenomyosis and endometriosis.
Copper Intrauterine Device (Cu-IUD)
Devices & Duration : TT380 Standard (licensed for 10 years ) and TT380 Short (licensed for 5 years ).
Copper-IUD EC: Copper impairs sperm function and prevents fertilisation; it does not terminate an established pregnancy. Timing is assessed against intercourse and estimated ovulation, with pregnancy exclusion and infection considerations before insertion.
Side Effects : Failure rate < 0.8 % < 0.8\% < 0.8% . Users frequently experience heavier menses, prolonged menstrual flow, and increased dysmenorrhoea. It is contraindicated in unexplained abnormal uterine bleeding, active pelvic infection, severe uterine anatomical distortion, and Wilson disease.
Combined hormonal methods: Discuss locally available formulations, contraindications, bleeding preferences and adherence. Do not assume every product licensed overseas is available in Australia.
Mechanism of Action
Oestrogen Component : Suppresses pituitary secretion of follicle-stimulating hormone (FSH), preventing dominant follicle selection and development.
Progestogen Component : Suppresses the mid-cycle LH surge, preventing ovulation. It also thickens cervical mucus to impede sperm penetration and induces endometrial atrophy.
MEC Category 1 : A condition for which there is no restriction for the use of the contraceptive method.
MEC Category 2 : A condition where the advantages of using the method generally outweigh the theoretical or proven risks.
MEC Category 3 : A condition where the theoretical or proven risks usually outweigh the advantages. Method is not recommended unless other methods are unavailable or unacceptable.
MEC Category 4 : A condition that represents an unacceptable health risk ( Absolute Contraindication ).
Absolute Contraindications (MEC 4) for Combined Hormonal Contraceptives
Migraine with Aura at Any Age : Conveys an unacceptably high relative and absolute risk of ischaemic stroke due to the synergistic prothrombotic and vasoconstrictive effects of exogenous oestrogens.
Severe Hypertension : Systolic blood pressure ≥ 160 mm Hg \ge 160\text{ mm Hg} ≥ 160 mm Hg or diastolic blood pressure ≥ 100 mm Hg \ge 100\text{ mm Hg} ≥ 100 mm Hg , or hypertension associated with end-organ vascular disease.
Smoking in Older Women : Age ≥ 35 years \ge 35\text{ years} ≥ 35 years smoking ≥ 15 cigarettes per day \ge 15\text{ cigarettes per day} ≥ 15 cigarettes per day (smoking < 15 < 15 < 15 cigarettes/day at age ≥ 35 \ge 35 ≥ 35 is MEC Category 3).
Venous Thromboembolism (VTE) : Current or past personal history of deep vein thrombosis or pulmonary embolism; known inherited or acquired thrombogenic mutations (e.g., Factor V Leiden, Prothrombin gene mutation, Antithrombin III deficiency, Antiphospholipid syndrome).
Ischaemic Heart Disease & Cerebrovascular Disease : Known current or past history of coronary artery disease, stroke, or transient ischaemic attack.
Breast cancer: Current disease contraindicates hormonal contraception. Past disease requires its specific MEC category and oncology advice; it is not the same as current disease.
Complicated Diabetes Mellitus : Diabetes with established microvascular complications (nephropathy, retinopathy, neuropathy) or disease duration > 20 years > 20\text{ years} > 20 years .
Severe Hepatic Impairment : Decompensated cirrhosis, severe acute viral hepatitis, or benign/malignant liver tumours (hepatocellular adenoma or carcinoma).
Prolonged Immobilization : Major surgery with prolonged bed rest.
Early Postpartum : < 6 weeks < 6\text{ weeks} < 6 weeks postpartum if breastfeeding (increases VTE risk and may suppress lactation).
Missed combined pills
Use the Australian product/clinical flowchart for the pill concerned. For a conventional combined pill, more than 48 hours since the previous active pill means a pill has been missed. This differs from a US rule framed as two pills or 48 hours after the next pill was due. Take the most recent missed active pill, continue the pack and use condoms or abstain until seven active pills have been taken consecutively. If the lapse is near the start after a hormone-free interval, assess recent unprotected sex and emergency contraception. If fewer than seven active pills remain, omit the hormone-free interval and start the next active pack. Progestogen-only pills have formulation-specific lateness windows; do not apply combined-pill rules to them.
Emergency Contraception (EC)
Emergency contraception is indicated following unprotected sexual intercourse (UPSI) or potential contraceptive failure to prevent unintended pregnancy.
Primary references (checked 7 October 2026): Australian combined-pill flowchart ; RANZCOG abortion guideline .